Intermittent Selumetinib for Uveal Melanoma

NCT02768766 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Uveal Melanoma

Interventions

DRUG: Selumetinib, 100mg
DRUG: Selumetinib, 125mg
DRUG: Selumetinib, 150mg
DRUG: Selumetinib, 175mg
DRUG: Selumetinib, 200mg
DRUG: Selumetinib, 225mg

Sponsor

Shaheer A. Khan

Collaborators

[object Object]
[object Object]